

Medical Coverage Policy | Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux



EFFECTIVE DATE: 01|01|2017

POLICY LAST UPDATED: 01|20|2021

OVERVIEW

A laparoscopically implanted ring composed of interlinked titanium beads with magnetic cores has been developed for the treatment of gastroesophageal reflux disease (GERD). The device is placed around the esophagus at the level of the gastroesophageal junction and is being evaluated in patients who have GERD symptoms, despite maximum medical therapy.

This policy is for the insertion only. For removal of the devices, please refer to the policy in the related policy section.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable.

POLICY STATEMENT

Medicare Advantage Plans

Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes

Commercial

Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for services not medically necessary/not covered .

BACKGROUND

Gastroesophageal reflux disease (GERD) is defined as reflux of stomach acid into the esophagus that causes symptoms and/or mucosal injury. GERD is a common medical disorder, with estimates of 10% to 20% prevalence in developed countries. The severity of GERD varies widely. Many patients have mild, intermittent symptoms that do not require treatment or only require episodic use of medications. Other patients have chronic, severe GERD that can lead to complications such as Barrett esophagus and esophageal cancer. For patients with severe disease, chronic treatment with acid blockers is an option. For some patients, medications are not adequate to control symptoms; other patients prefer to avoid the use of indefinite, possibly lifelong medications. Surgical treatments are available for these patients, primarily a Nissen fundoplication performed either laparoscopically or by open surgery. A number of less invasive procedures are also being evaluated as an intermediate option between medical therapy and surgery (see review 2.01.38 on endoscopic procedures).

The LINX Reflux Management System is composed of a small flexible band of 10 to 18 interlinked titanium beads with magnetic cores. Using standard laparoscopic techniques, the band is placed around the esophagus at the level of the gastroesophageal junction. The magnetic attraction between the beads is intended to augment the lower esophageal sphincter to prevent gastric reflux into the esophagus, without compressing

the esophageal wall. It is proposed that swallowing food or liquids creates sufficient pressure to overcome the magnetic bond between the beads, allowing the beads to separate and temporarily increase the size of the ring. The target population is patients who have GERD symptoms despite maximum medical therapy (eg, proton pump inhibitors) but who do not want to risk the adverse effects of a surgical procedure like Nissen fundoplication. Adverse events of the LINX Reflux Management System may include dysphagia or odynophagia. The device can be removed by a laparoscopic procedure if severe adverse events occur or if magnetic resonance imaging is needed for another condition.

For individuals who have GERD who receive magnetic sphincter augmentation (MSA), the evidence includes prospective and retrospective observational comparative studies, 2 single-arm interventional trials, and a number of single-arm observational studies. Relevant outcomes are symptoms, change in disease status, medication use, and treatment-related morbidity. In the 2 single-arm, uncontrolled manufacturer-sponsored studies submitted to the U.S. Food and Drug Administration for device approval, subjects showed improvements in Gastroesophageal Reflux Disease–Health Related Quality of Life (GERD-HRQL) scores and reduced proton pump inhibitor (PPI) use. Similarly, observational comparative studies, most often comparing magnetic sphincter augmentation (MSA) with laparoscopic Nissen fundoplication, generally have shown that GERD-HRQL scores do not differ significantly between fundoplication and MSA, and patients are able to reduce PPI use after MSA. However, the comparative studies are retrospective and nonrandomized, may be affected by selection bias, and the subjective outcome measures used in these studies (eg, the GERD-HRQL scores) may be biased. A randomized trial is in progress; it will compare treatment with the MSA and treatment with double-dose PPIs. Randomized comparisons of MSA with laparoscopic Nissen fundoplication are also needed to evaluate the relative risk-benefit of these 2 procedures. The evidence is insufficient to determine the effects of the technology on health outcomes.

REGULATORY STATUS

In 2012, the LINX™ Reflux Management System (Torax Medical, Shoreview, MN) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process for patients diagnosed with gastroesophageal reflux disease (GERD), as defined by abnormal pH testing, and who continue to have chronic GERD symptoms despite maximum therapy for the treatment of reflux. FDA initially required 5-year follow-up of 100 patients from the investigational device exemption pivotal study to evaluate safety and efficacy of the device, which was completed in March 2016. FDA product code: LEI.

CODING

Medicare Advantage Plans and Commercial

The following code is not medically necessary

43284 - Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed

RELATED POLICIES

Removal of Non-Covered Implantable Devices

PUBLISHED

Provider Update, March 2021

Provider Update, April 2020

Provider Update, April 2019

Provider Update, May 2018

Provider Update, April 2017

REFERENCES:

1. U.S. Food and Drug Administration. Class 2 Device Recall LINX Reflux Management System. May 31, 2018. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=163589>. Accessed September 28, 2020.

2. Guidozi N, Wiggins T, Ahmed AR, et al. Laparoscopic magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: systematic review and pooled analysis. *Dis Esophagus*. Nov 13 2019; 32(9). PMID 31069388
3. Aiolfi A, Asti E, Bernardi D, et al. Early results of magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: Systematic review and meta-analysis. *Int J Surg*. Apr 2018; 52: 82-88. PMID 29471155
4. Bell R, Lipham J, Louie BE, et al. Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial. *Clin Gastroenterol Hepatol*. Jul 2020; 18(8): 1736-1743.e2. PMID 31518717
5. Bell R, Lipham J, Louie B, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. *Gastrointest Endosc*. Jan 2019; 89(1): 14-22.e1. PMID 30031018
6. U.S. Food and Drug Administration, Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee. LINXTM Reflux Management System. 2012; <https://wayback.archive-it.org/7993/20170113140208/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/Gastroenterology-UrologyDevicesPanel/UCM286236.pdf>. Accessed September 23, 2020.
7. Reynolds JL, Zehetner J, Bildzukewicz N, et al. Magnetic sphincter augmentation with the LINX device for gastroesophageal reflux disease after U.S. Food and Drug Administration approval. *Am Surg*. Oct 2014; 80(10): 1034-8. PMID 25264655
8. Warren HF, Louie BE, Farivar AS, et al. Manometric Changes to the Lower Esophageal Sphincter After Magnetic Sphincter Augmentation in Patients With Chronic Gastroesophageal Reflux Disease. *Ann Surg*. Jul 2017; 266(1): 99-104. PMID 27464617
9. Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. *N Engl J Med*. Feb 21 2013; 368(8): 719-27. PMID 23425164
10. Ganz RA, Edmundowicz SA, Taiganides PA, et al. Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. *Clin Gastroenterol Hepatol*. May 2016; 14(5): 671-7. PMID 26044316
11. Alicuben ET, Bell RCW, Jobe BA, et al. Worldwide Experience with Erosion of the Magnetic Sphincter Augmentation Device. *J Gastrointest Surg*. Aug 2018; 22(8): 1442-1447. PMID 29667094
12. Smith CD, DeVault KR, Buchanan M. Introduction of mechanical sphincter augmentation for gastroesophageal reflux disease into practice: early clinical outcomes and keys to successful adoption. *J Am Coll Surg*. Apr 2014; 218(4): 776-81. PMID 24529809
13. Rona KA, Reynolds J, Schwameis K, et al. Efficacy of magnetic sphincter augmentation in patients with large hiatal hernias. *Surg Endosc*. May 2017; 31(5): 2096-2102. PMID 27553803
14. Ferrari D, Asti E, Lazzari V, et al. Six to 12-year outcomes of magnetic sphincter augmentation for gastroesophageal reflux disease. *Sci Rep*. Aug 13 2020; 10(1): 13753. PMID 32792508
15. SAGES: Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). TAVAC Category: Safety and Effectiveness. LINX Reflux Management System. 2017; <https://www.sages.org/publications/tavac/tavac-safety-and-effectiveness-analysis-linx-reflux-management-system/>. Accessed September 23, 2020.
16. Gottlieb KT, Banerjee S, Barth BA, et al. Magnets in the GI tract. *Gastrointest Endosc*. Oct 2013; 78(4): 561-7. PMID 24054738

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

